Rebastinib

Overview

Rebastinib is an orally bioactive inhibitor of Bcr-Abl that binds to and inhibits Bcr-Abl fusion oncoprotein. Rebastinib changes the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation. It also exhibits inhibitory activity at SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Bcr-Abl

Product Information

• Catalog No.: B0084-307739
• CAS No.: 1020172-07-9
• Molecular Formula: C30H28FN7O3
• Molecular Weight: 553.598
• Purity: ≥98%

Source

Original product source